Tarlatamab
Noted OncologyAuthority RequiredSecond-line line
Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (second-line or subsequent treatment).
1
Submissions
1 resub
2026–26
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis
Decisions on record
- Meeting May 2026 Noted Extensive-stage small cell lung cancer with disease progression on or after first line platinum-based chemotherapy no PSD
- Meeting Mar 2026 Not recommended Extensive-stage small cell lung cancer (ES-SCLC)
- Meeting Jul 2025 Withdrawn Small cell lung cancer third-line plus extensive-stage no PSD
- Meeting Mar 2025 Withdrawn Small cell lung cancer, extensive-stage, third-line plus treatment no PSD
Cost-effectiveness
ICER value is redacted (commercially sensitive). The submission contained a cost-effectiveness analysis versus topotecan, but the specific ICER is not published in this PSD.
Decision context
PopulationAdult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy, second-line or subsequent treatment.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Not recommended | topotecan | — | RCT |